AKT1 and ovarian carcinoma: Finally, in ovarian cancer resistant to bevacizumab, Guerrouehan et al. demonstrated that Protein Kinase B (PKB also known as AKT)-mediated endothelial factors secretion (where FGF-2 plays a major role) creates an autocrine loop that avoids bevacizumab inhibition.